| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC3025 |
| Trial ID | NCT05367843 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | PRIME-2-CoV_Beta |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase 1, Dose Ranging Study Assessing the Safety, Tolerability, Immunogenicity of Vaccine Candidate PRIME-2-CoV_Beta, Orf Virus Expressing SARS-CoV-2 Spike and Nucleocapsid Proteins (ORFEUS Study) |
| Year | 2022 |
| Country | United States|Germany |
| Company sponsor | Speransa Therapeutics |
| Other ID(s) | D1701-VrV-101|2021-005219-30 |
| Cohort1: Pre-vaccinated | |||||
|
|||||
| Cohort2: Vaccine-naïve | |||||
|
|||||